Rocket Pharmaceuticals, Inc. reports developments in rare-disease genetic medicines, including its commercial-stage therapy KRESLADI for pediatric patients with severe leukocyte adhesion deficiency-I and its broader pipeline of investigational gene therapies. Company updates commonly address FDA actions, clinical-program progress, regulatory submissions, and financial results tied to research, development, and commercial readiness.
Recurring news themes include the AAV cardiovascular portfolio, such as RP-A501 for Danon disease, RP-A601 for PKP2-arrhythmogenic cardiomyopathy, and RP-A701 for BAG3-related dilated cardiomyopathy. Rocket also reports capital and balance-sheet actions, including monetization of its Rare Pediatric Disease Priority Review Voucher, as well as presentations at healthcare conferences.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has expanded its leadership team to bolster its gene therapy initiatives. Jonathan Schwartz, M.D., has been appointed as Chief Gene Therapy Officer, while Mark White, MB.ChB, joins as Chief Medical Officer. Schwartz, previously Chief Medical Officer, will enhance research and clinical strategies for gene therapy applications. White brings over 25 years of experience from AstraZeneca, focusing on late-stage development and commercialization. This leadership evolution aims to advance Rocket's pipeline of gene therapies for rare disorders and support its transition toward commercial operations.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has announced CEO Gaurav Shah's participation in the Genetic Medicines Corporate Panel at the Cowen Health Care Conference in Boston, MA, on March 6, 2023, at 10:30 a.m. ET. The conference will feature a live audio webcast accessible via the Investors section on their website. Rocket is focused on developing genetic therapies for rare disorders, including Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency, utilizing lentiviral and adeno-associated virus-based technologies.
For more details, visit Rocket's website.
Rocket Pharmaceuticals (NASDAQ: RCKT) announced significant advancements in its gene therapy pipeline for rare disorders, reporting strong clinical results across four programs, including Danon Disease and Fanconi Anemia. The company secured Regenerative Medicine Advanced Therapy (RMAT) designation for RP-A501, with a pivotal trial expected in Q2 2023. Financially, Rocket reported cash reserves of approximately $400M, sufficient to support operations through 2024. Notably, their R&D expenses rose to $165.6M for the year, contributing to a net loss of $221.9M. Additionally, the acquisition of Renovacor led to expanded capabilities in AAV-based therapies.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced that CEO Gaurav Shah, M.D. will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Thursday, February 16, at 2:20 p.m. ET. This event will discuss Rocket's innovative pipeline of genetic therapies aimed at rare disorders including Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency. A live audio webcast will be available on the company's website, and a replay will follow the event. Rocket focuses on developing advanced genetic therapies to address high unmet medical needs in rare diseases.
Rocket Pharmaceuticals (NASDAQ: RCKT) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its gene therapy RP-A501, aimed at treating Danon Disease, a serious genetic cardiac condition. This designation is based on positive data from the Phase 1 trial, indicating the therapy's potential safety and efficacy. The RMAT designation facilitates expedited review and development, including intensive FDA guidance and potential accelerated approval pathways. Rocket plans to initiate a Phase 2 pivotal trial in Q2 2023, building on promising Phase 1 results that showed improved clinical parameters in treated patients.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced key advancements in its gene therapy pipeline including RP-A601 for treating arrhythmogenic cardiomyopathy (PKP2-ACM), with an IND submission anticipated in Q2 2023. The company reported promising Phase 1 results for Danon Disease, showing significant clinical improvements and biomarker stability. The expected BLA filings for Fanconi Anemia and Leukocyte Adhesion Deficiency are scheduled for Q2 and Q4 2023, respectively. Rocket is well-capitalized with $401 million in cash, ensuring operational funding through 2024.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is set to present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 2:15 p.m. PT. CEO Gaurav Shah will represent the company, known for its innovative approach to developing genetic therapies aimed at rare childhood disorders. The live audio webcast will be accessible under the Investors section of the company's website, with a replay available post-conference. Rocket's pipeline includes therapies for Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and Danon Disease.
Rocket Pharmaceuticals (NASDAQ: RCKT) announced updates regarding its gene therapy, RP-A501, for Danon Disease following an end-of-Phase 1 meeting with the FDA. The company plans to advance with a pivotal trial utilizing a biomarker-based composite endpoint, aiming to initiate the study in 1H 2023. The Phase 1 trial showed favorable results with consistent improvements in biomarkers and quality of life across both pediatric and adult patients. The therapy is designed to address a significant unmet medical need in a condition with no current targeted treatments.
Rocket Pharmaceuticals (NASDAQ: RCKT) announced promising updates on its lentiviral gene therapy programs at the American Society of Hematology (ASH) Annual Meeting, with both RP-L102 for Fanconi Anemia and RP-L301 for Pyruvate Kinase Deficiency showing significant success. Six out of ten evaluated FA patients demonstrated sustained genetic correction and hematologic stabilization after 12-36 months. Furthermore, both patients treated with RP-L301 exhibited normalized hemoglobin levels at 24 months, ensuring an improved quality of life. Regulatory filings are anticipated in 2023.
Rocket Pharmaceuticals, Inc. has announced the acquisition of Renovacor, Inc., aimed at enhancing its leadership in AAV-based cardiac gene therapy. Under the merger terms established on September 19, 2022, Renovacor shareholders received 0.1763 shares of Rocket for each Renovacor share. The acquisition adds Renovacor's leading program, REN-001, targeting BAG3-associated dilated cardiomyopathy, which has no current treatments addressing its underlying causes, to Rocket's pipeline. Renovacor shares ceased trading on the NYSE as of December 1, 2022.